MARKET

LNTH

LNTH

Lantheus Holding
NASDAQ
78.22
-0.78
-0.99%
After Hours: 78.50 +0.28 +0.36% 19:00 05/24 EDT
OPEN
79.99
PREV CLOSE
79.00
HIGH
80.72
LOW
78.10
VOLUME
857.19K
TURNOVER
0
52 WEEK HIGH
100.48
52 WEEK LOW
50.20
MARKET CAP
5.42B
P/E (TTM)
11.94
1D
5D
1M
3M
1Y
5Y
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 2d ago
Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus
Lantheus Holdings, Inc. Excels in radiopharmaceuticals, with PYLARIFY's dominance in PSMA PET imaging. The company's recent Q1 2024 results saw revenue grow 23% YoY. The market for radiopharaceuticals is expanding beyond all expectations. Lant heus could be a long-term winner.
Seeking Alpha · 3d ago
Eli Lilly inks radiopharma deal worth up to $1.1B with Aktis
Healthcare Eli Lilly inks radiopharma deal worth up to $ with Aktis Oncology. Aktis will receive a $60M upfront payment. Eli Lilly will leverage Aktis’ radiopharmaceutical platform to develop cancer-targeting drugs.
Seeking Alpha · 5d ago
Weekly Report: what happened at LNTH last week (0513-0517)?
Weekly Report · 6d ago
Lantheus Stock (NASDAQ:LNTH): High Growth Powered by Radiopharma Innovations
TipRanks · 05/15 23:57
Lantheus Holdings Names Jeffrey Humphrey to Be Medical Chief
Jeffrey Humphrey named chief medical officer of Lantheus Holdings. Previous CMO Jean-Claude Provost was named chief science officer. Humphrey has spent more than 20 years at pharmaceutical companies, Lant heus says. The company makes medical imaging products.
Dow Jones · 05/15 21:17
Lantheus Announces Executive Team Reshuffle with New CSO
TipRanks · 05/15 21:03
Press Release: Lantheus Announces Executive Appointments to Accelerate Innovation
Lantheus Announces Executive Appointments to Accelerate Innovation Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer. Dr. Humphreys has more than 30 years of experience in clinical oncology, neuroscience and drug discovery.
Dow Jones · 05/15 20:30
More
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.

Webull offers Lantheus Holdings Inc stock information, including NASDAQ: LNTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LNTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LNTH stock methods without spending real money on the virtual paper trading platform.